Translating science
into innovative
diagnostic solutions
Latest news
NY Governor's Office
Upstate Medical gets FDA approval for Wider Use of its Saliva Swab COVID-19 Test
CNY BUSINESS JOURNAL
NYS GOVERNOR'S OFFICE
Governor Cuomo and Chancellor Malatras Announce FDA Approval for COVID-19 Saliva Swab Test
NYS GOVERNOR'S OFFICE
Quadrant Biosciences Receives FDA Emergency Authorization for New COVID-19 Saliva Test
CISION PR NEWSWIRE
Cape Vincent native heads Quadrant Biosciences, lab company on cutting edge of COVID research
NNY 360
Renowned autism researcher Dr. Thomas Frazier joins Quadrant Biosciences Clinical Advisory Board
EIN PRESSWIRE
EIN PRESSWIRE
Our aim is to develop solutions for important global health issues
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson’s disease and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. Clarifi ASD, an autism diagnostic aid, is the first product to launch commercially from this platform. Clarifi ASD is now available through prescription; details on how to obtain testing are available on Clarifi’s website.
Finally, we are involved in three significant, complementary COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S.






Be part of a study
Be part of a study
Autism research study
Children ages 18 months to 48 months with an autism diagnosis, developmental delays, or a suspicion of autism are eligible.
Parkinson’s Study
Help us learn how to better diagnose Parkinson’s Disease at an earlier stage.